Bio-Techne Corporation


SKU: TECH Category:


This is our first report on Bio-Techne Corporation. The company delivered a strong financial performance in the past quarter, surpassing Wall Street expectations in terms of both, revenues as well as earnings. Though the tight labor market was a constraint, the company made progress in hiring for its growth plan. Bio-Techne Corporation recently announced the unveiling of the CE-IVD marked RNAscopeTM ISH Probe High-Risk HPV Assay for neck and head cancer. For the biopharma end-users, the demand for high-quality solutions and products is quite strong. The company also went on to acquire Namocell. In the quarter, the GMP protein business of the company increased by more than 160%. With its innovative GMP manufacturing facility that is open for business, Bio-Techne is well-positioned for meeting the anticipated growth demand. The company’s related consumable hold-through and its instruments grew more than 30%, which reflects quite a strong biopharma environment. The ExoDx Volume in this quarter was the highest, and it also made advancements on the ExoDx reimbursement front. We initiate coverage on Bio-Techne Corporation with a ‘Hold’ rating.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!